Trial Profile
A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs ARCT 021 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Arcturus Therapeutics
- 07 Jul 2022 Status changed from recruiting to discontinued.
- 01 Feb 2021 New trial record